
The FDA has stated that it does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on tirzepatide's inclusion on the FDA drug shortage list. Compounding pharmacies should still exercise their own ...